Nicole Brudos Ferrara @nicoleferrara
Activity by Nicole Brudos Ferrara @nicoleferrara
“I was having trouble breathing; just taking a deep breath was difficult,” she remembers.
Kathi went to her local doctor’s office and was prescribed a round of antibiotics and steroids to address what the doctor considered a respiratory issue.
“I felt better for a little while — but then by March, I just bloated up and was having increasing difficulty breathing,” she says. “It was terrible. I just thought, something is horribly wrong.”
As the symptoms progressed, Kathi’s concern grew, and on March 18, 2015, [...]
Using a novel zebrafish model, Mayo Clinic researchers have identified a molecule called GAB2 that is highly represented in the malignant cells of many patients with neuroblastoma. Neuroblastoma is a cancer that develops from immature neural cells found in several areas of the body.
The researchers believe that overexpression of GAB2 signals the activation of a protein called SHP2 that drives and maintains neuroblastoma.
"Neuroblastoma is one of the most common solid tumors in infants," says Shizhen (Jane) Zhu, Ph.D., who led the research team. Dr. Zhu says the disease accounts for 10 to 13 percent of all childhood cancer deaths.
Updated guidelines underscore need to identify the most optimal candidates for HER2-directed therapy.
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test positive for HER2 breast cancer, Mayo Clinic researchers have found.
The researchers published their HER2 breast cancer study results online July 25, 2016, in the Journal of Clinical Oncology.
Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2 positive and can be treated with drugs such as Herceptin that target the HER2 protein. HER2-positive cancers tend to be more aggressive and spread more quickly than do other breast cancers.
Drugs targeting the P13K-mTOR pathway add benefit when combined with standard R-CHOP therapy.
The drug everolimus can be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma, according to the results of a pilot study by Mayo Clinic researchers.
The researchers published their study findings in the July 2016 issue of The Lancet Haematology.
Patrick B. Johnston, M.D., [...]
A team of Mayo Clinic researchers has identified evidence of bacteria in breast tissue and found differences between women with and without breast cancer.
These research findings were published in the August 3, 2016, issue of Scientific Reports.
"Our research found that breast tissue samples obtained in the operating room under sterile conditions contain bacterial DNA, even when there is no sign of infection," said Tina J. Hieken, M.D., a breast surgical oncologist at Mayo Clinic in Rochester, Minnesota. "Furthermore, we identified significant differences in the breast tissue microbiome of women with cancer versus women without cancer and the [...]
Researchers on Mayo Clinic's campus in Jacksonville, Florida, have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
Radiation plus three-drug combo boosts progression-free survival and overall survival.
Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than did patients who received radiation therapy alone.
These are the results of a clinical trial called Radiation Therapy Oncology Group (RTOG) 9802 that were published in the April 7, 2016, issue of the New England Journal of Medicine.
"This is the first phase III trial to demonstrate conclusively a [...]
The post below was written by Toni Kay Mangskau, clinical trials referral coordinator at Mayo Clinic Cancer Center and an active volunteer for the American Cancer Society and the National Patient Advocate Foundation.
September 2014 was the 10th anniversary of the death of my brother-in-law, Bruce, from cancer. I carry close to my heart a family conversation about Bruce urgently looking for any clinical trial opportunities in the world so he could possibly have more time to live. Unfortunately, his health declined and he was hospitalized in intensive care. As I walked into his hospital room, Bruce was surrounded by his wife, mother and children. Except for the medical machines, there was a [...]
Mayo Clinic in Rochester, Minn., is seeking volunteers for a clinical trial for patients with human papillomavirus (HPV) positive tonsil or tongue (oropharynx) cancer whose disease has not spread outside of the neck. The purpose of the study is to find out if reducing treatment time and dosage can control the cancer while decreasing short-term and long-term side effects associated with treatment.
Who is eligible?
You may be eligible to participate in this study if you: